In the Senate of the United States, 

December 9, 2015. 

Resolved, That the bill from the House of Representatives (H.R. 2820) entitled ‘‘An Act to reauthorize the Stem 

Cell Therapeutic and Research Act of 2005, and for other 

purposes.’’, do pass with the following 

AMENDMENT: 

Strike out all after the enacting clause and insert: 

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Stem Cell Therapeutic 

3 and Research Reauthorization Act of 2015’’. 

4 SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 

5 TRANSPLANTATION PROGRAM. 

6 (a) IN GENERAL.—Section 379(d)(2)(B) of the Public 

7 Health Service Act (42 U.S.C. 274k(d)(2)(B)) is amended— 

8 (1) by striking ‘‘remote collection’’ and inserting 

9 ‘‘collection’’; and 

10 (2) by inserting ‘‘including remote collection,’’ 

11 after ‘‘cord blood units,’’. 
2 

† HR 2820 EAS 

1 (b) AUTHORIZATION OF APPROPRIATIONS.—Section 

2 379B of the Public Health Service Act (42 U.S.C. 274m) 

3 is amended— 

4 (1) by striking ‘‘$30,000,000 for each of fiscal 

5 years 2011 through 2014 and’’; and 

6 (2) by inserting ‘‘and $30,000,000 for each of fis7 cal years 2016 through 2020’’ before the period at the 

8 end. 

9 (c) SECRETARY REVIEW ON STATE OF SCIENCE.—The 

10 Secretary of Health and Human Services, in consultation 

11 with the Director of the National Institutes of Health, the 

12 Commissioner of the Food and Drug Administration, and 

13 the Administrator of the Health Resources and Services Ad14 ministration, including the Advisory Council on Blood 

15 Stem Cell Transplantation established under section 379(a) 

16 of the Public Health Service Act (42 U.S.C. 274k(a)), and 

17 other stakeholders, where appropriate given relevant exper18 tise, shall conduct a review of the state of the science of 

19 using adult stem cells and birthing tissues to develop new 

20 types of therapies for patients, for the purpose of consid21 ering the potential inclusion of such new types of therapies 

22 in the C.W. Bill Young Cell Transplantation Program (es23 tablished under such section 379) in addition to the con24 tinuation of ongoing activities. Not later than June 30, 

25 2019, the Secretary shall submit to the Committee on 
3 

† HR 2820 EAS 

1 Health, Education, Labor, and Pensions of the Senate and 

2 the Committee on Energy and Commerce of the House of 

3 Representatives recommendations on the appropriateness of 

4 such new types of therapies for inclusion in the C.W. Bill 

5 Young Cell Transplantation Program. 

6 SEC. 3. CORD BLOOD INVENTORY. 

7 Section 2 of the Stem Cell Therapeutic and Research 

8 Act of 2005 (42 U.S.C. 274k note) is amended— 

9 (1) in subsection (a), by striking ‘‘one-time’’; 

10 (2) by striking subsection (c); 

11 (3) by redesignating subsections (d) through (h) 

12 as subsections (c) through (g), respectively; 

13 (4) in subsection (d) (as so redesignated)— 

14 (A) in paragraph (1), by striking ‘‘para15 graphs (2) and (3)’’ and inserting ‘‘paragraphs 

16 (2), (3), and (4)’’; 

17 (B) in paragraph (2)(B), by striking ‘‘sub18 section (d)’’ and inserting ‘‘subsection (c)’’; and 

19 (C) by adding at the end the following: 

20 ‘‘(4) CONSIDERATION OF BEST SCIENCE.—The 

21 Secretary shall take into consideration the best sci22 entific information available in order to maximize the 

23 number of cord blood units available for transplant 

24 when entering into contracts under this section, or 
4 

† HR 2820 EAS 

1 when extending a period of funding under such a con2 tract under paragraph (2). 

3 ‘‘(5) CONSIDERATION OF BANKED UNITS OF CORD

4 BLOOD.—In extending contracts pursuant to para5 graph (3), and determining new allocation amounts 

6 for the next contract period or contract extension for 

7 such cord blood bank, the Secretary shall take into ac8 count the number of cord blood units banked in the 

9 National Cord Blood Inventory by a cord blood bank 

10 during the previous contract period, in addition to 

11 consideration of the ability of such cord blood bank to 

12 increase the collection and maintenance of additional, 

13 genetically diverse cord blood units.’’; 

14 (5) in subsection (f) (as so redesignated)— 

15 (A) by striking paragraph (4); and 

16 (B) by redesignating paragraphs (5) and 

17 (6) as paragraphs (4) and (5), respectively; and 

18 (6) in subsection (g) (as so redesignated)— 

19 (A) in paragraph (1)— 

20 (i) by striking ‘‘$23,000,000 for each of 

21 fiscal years 2011 through 2014 and’’; and 

22 (ii) by inserting ‘‘and $23,000,000 for 

23 each of fiscal years 2016 through 2020’’ be24 fore the period at the end; and 

25 (B) by striking paragraph (2). 
5 

† HR 2820 EAS 

1 SEC. 4. DETERMINATION ON THE DEFINITION OF HUMAN 

2 ORGAN. 

3 Not later than one year after the date of enactment 

4 of this Act, the Secretary of Health and Human Services 

5 shall issue determinations with respect to the inclusion of 

6 peripheral blood stem cells and umbilical cord blood in the 

7 definition of human organ. 

Attest: 

Secretary. 
114TH CONGRESS 

1ST SESSION H.R. 2820 

AMENDMENT